Omada Health (NASDAQ:OMDA) Price Target Raised to $28.00

Omada Health (NASDAQ:OMDA) had its price objective upped by Needham & Company LLC from $26.00 to $28.00 in a research report released on Friday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on OMDA. Canaccord Genuity Group upped their price target on Omada Health from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Barclays boosted their price objective on Omada Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Omada Health in a report on Wednesday, October 8th. Evercore ISI set a $27.00 price target on shares of Omada Health in a research note on Wednesday, October 8th. Finally, Robert W. Baird started coverage on shares of Omada Health in a research report on Friday, September 5th. They issued a “neutral” rating and a $24.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Omada Health Stock Up 2.4%

Omada Health stock traded up $0.48 during mid-day trading on Friday, reaching $20.79. 298,215 shares of the company’s stock were exchanged, compared to its average volume of 582,482. Omada Health has a twelve month low of $14.14 and a twelve month high of $28.40. The stock’s fifty day simple moving average is $23.70.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The business had revenue of $61.37 million for the quarter, compared to analyst estimates of $55.17 million.

Institutional Trading of Omada Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Omada Health in the 2nd quarter valued at about $32,000. Strs Ohio purchased a new stake in Omada Health in the third quarter valued at approximately $38,000. Rakuten Investment Management Inc. acquired a new stake in shares of Omada Health in the third quarter valued at approximately $49,000. JPMorgan Chase & Co. purchased a new position in shares of Omada Health during the third quarter worth approximately $82,000. Finally, Rhumbline Advisers acquired a new position in shares of Omada Health in the 3rd quarter valued at $176,000.

About Omada Health

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.